DALLAS and NEW YORK, Oct. 27,
2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a
clinical stage biopharmaceutical company using its proprietary
RADR® artificial intelligence ("A.I.") platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced a collaboration that will
power A.I.-driven computational research for oncology-focused drug
discovery and development with Code Ocean, the leading
computational research environment for sharing scientific
discoveries. By leveraging Code Ocean's Compute Capsule®
technology, the strategic approach is expected to further power
Lantern Pharma's RADR® platform for faster, more
collaborative discoveries from billions of
RADR® data points, as well as data and insights
from Lantern's network of collaborators.
Computational researchers today are challenged with analyzing
big data due to too many disparate tools, lack of specialized
coding experience, and challenging, cumbersome DevOps processes
required to organize and securely share research. Through this
collaboration, Lantern Pharma is expected to benefit from
significant efficiencies in development time and cost, as well as
increased reproducibility from Code Ocean's platform. The Code
Ocean platform will offer an easy to use, collaborative research
experience with an integrated development environment, secure
repository, and portable Compute Capsule® technology for
guaranteed reproducibility.
"I'm thrilled to be working with a leading-edge technology
partner like Lantern Pharma," said Simon Adar, Co-Founder and CEO
of Code Ocean. "This collaboration truly enables large-scale,
high-throughput collaboration both internally at Lantern and also
with their leading research partners to accelerate the pace of
oncology drug discovery."
"It's clear that science and discovery need to be fully
integrated using the latest tools and technologies to reduce costs,
speed-up development, and increase probability of success," said
Panna Sharma, President & CEO of
Lantern Pharma. "We selected Code Ocean as we believe this
collaboration will provide our scientists, researchers, data
engineers and collaborators with a best-in-class, reproducible and
highly secure platform environment to maximize the power and
usability of our RADR® A.I. platform to improve and
enhance the research experience. Bringing together our proprietary
A.I. with Code Ocean's Compute Capsule® technology we
believe will allow us and other researchers to take collaborative
drug development further and faster than ever before."
Lantern leverages advances in machine learning, genomics and
artificial intelligence to develop oncology therapies by using its
proprietary A.I. platform, RADR®, to discover biomarker signatures
aimed at helping identify patients more likely to respond to its
pipeline of cancer therapeutics. Working within the Code Ocean
platform is expected to help increase team productivity and enhance
Lantern Pharma's ability to collaborate more rapidly with industry
leading partners, such as the National Cancer Institute,
Georgetown University, Johns Hopkins and Fox Chase Cancer Center, within a
secure and agile research environment.
The Code Ocean platform does not require the user to be an IT
expert to utilize the software properly. By integrating the
essential triplet– code, data and a computing environment– Code
Ocean offers the most complete platform for computational research
that's on the market. Code Ocean's unique Compute Capsules provide
a fundamentally easier and more efficient way for researchers to
create and safely share their work, which is essential to moving
science forward. This, combined with Lantern Pharma's billions of
data points and growing library of algorithms designed for oncology
drug development, will allow researchers to have faster access to
more data than ever before, without being overwhelmed by massive
amounts of data management or computational structure.
About Code Ocean
Code Ocean is where great computational research is created,
organized and shared in one place. The Code Ocean platform provides
the best way for research teams to standardize research workflow,
and to track and reproduce all computations and discoveries. By
making it easier and more efficient for researchers to collaborate,
Code Ocean improves reproducibility, optimizes return on IT
investment, and saves time by automating repetitive functions. For
more information please visit: www.codeocean.com and Twitter
@CodeOceanHQ.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary
RADR® A.I. platform and machine learning to
discover biomarker signatures that identify patients most likely to
respond to its pipeline of genomically targeted therapeutics.
Lantern is currently developing four drug candidates and an ADC
program across eight disclosed tumor targets, including two phase 2
programs. By targeting drugs to patients whose genomic profile
identifies them as having the highest probability of benefiting
from the drug, Lantern's approach represents the potential to
deliver best-in-class outcomes. More information is available
at: www.lanternpharma.com and Twitter @lanternpharma.
Forward-looking Statements
This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. These
forward-looking statements include, among other things, statements
relating
to: future events; the potential advantages of Lantern's RADR® platform
in identifying
drug candidates and patient populations that are likely to respond to a
drug candidate; estimates regarding the development timing for
Lantern's drug candidates and ADC development program; Lantern's
research and development efforts of its internal drug
discovery programs; Lantern's intention to leverage artificial
intelligence, machine learning and genomic data to streamline
and transform the pace, risk and cost of oncology
drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
Lantern's plans to discover and develop drug candidates and
to maximize their commercial potential by advancing such drug
candidates itself or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as
"anticipate," "believe," "contemplate," "could," "estimate,"
"expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target,"
"goal," "objective," "aim," "should," "will," "would," or
the negative of these words or other similar expressions) should
be considered forward-looking statements. There are a number
of important factors that could cause actual results to differ
materially from those indicated by the forward-looking statements,
such as (i) the impact of the
COVID-19 pandemic, (ii) the risk that none of Lantern's product
candidates has received FDA marketing approval, and Lantern
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for its product
candidates, (iii) the risk that no drug product based on Lantern's
proprietary RADR A.I. platform has received FDA
marketing approval or otherwise been incorporated into a
commercial product, and (iv) those other factors set forth in
the Risk Factors section in Lantern's Annual Report on Form 10-K
for the year ended December 31, 2020, filed with the
Securities and Exchange Commission on March
10, 2021. You may access Lantern's Annual Report on
Form 10-K for the year ended December 31,
2020 under the investor SEC filings tab
of its
website at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, neither
Lantern nor Code Ocean can give
any assurances that such forward-looking statements will prove to be accurate, or that any other results
or events projected or contemplated by such forward-looking
statements will in fact occur, and investors are cautioned not
to place undue reliance on these statements. All
forward-looking statements in this press release represent the
respective judgment of Lantern and Code Ocean as of the date
hereof, and, except as otherwise required by law, Lantern and Code
Ocean disclaim any obligation to update any forward-looking
statements to conform the statement to actual results
or changes in their expectations.
Code Ocean Contact:
David
Butler
david@codeocean.com
Lantern Pharma Contacts:
Investor Relations
David
Waldman, Crescendo Communications, LLC
IR@lanternpharma.com
Public Relations
Nicholas Koulermos, 5W Public
Relations
lantern@5wpr.com
View original
content:https://www.prnewswire.com/news-releases/code-ocean-selected-by-lantern-pharma-to-power-ai-and-computational-biology-research--data-driven-oncology-drug-development-collaborations-301409807.html
SOURCE Lantern Pharma